Bioanalizės sistemos - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 9,175 | 130,467 | 30,659 | 535,051 | 179,484 | 283,049 | 115,427 | 303,616 |
| Profit before tax | - | - | - | - | - | - | - | - |
| Net profit | 186 | 14,727 | 567 | 138,532 | 39,778 | 2,243 | -102,210 | 25,670 |
| Equity | 2,033 | 16,760 | 17,326 | 155,858 | 175,235 | 172,461 | 70,253 | 95,922 |
| Liabilities | 4,563 | 4,241 | 47,892 | 75,893 | 54,731 | 70,632 | 100,421 | 114,610 |
| Non-current assets | 534 | 4,469 | 29,350 | 652,837 | 519,122 | 385,457 | 209,265 | 47,237 |
| Current assets | 6,062 | 16,532 | 35,868 | 298,271 | 161,765 | 145,961 | 97,874 | 161,160 |
| Total assets | 6,596 | 21,001 | 65,218 | 951,108 | 680,887 | 531,418 | 307,139 | 208,397 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 44,512 | 13,442 | 13,506 |
| Social insurance contributions | - | - | - | - | - | 13,792 | 17,972 | 22,335 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -49.2% | +1322.0% | -76.5% | +1645.2% | -66.5% | +57.7% | -59.2% | +163.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 2.8% | 70.1% | 0.9% | 14.6% | 5.8% | 0.4% | -33.3% | 12.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 9.1% | 87.9% | 3.3% | 88.9% | 22.7% | 1.3% | -145.5% | 26.8% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 2.0% | 11.3% | 1.8% | 25.9% | 22.2% | 0.8% | -88.5% | 8.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 2.2 | 0.3 | 2.8 | 0.5 | 0.3 | 0.4 | 1.4 | 1.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 3,238 | 48,925 | 7,665 | 91,724 | 14,077 | 40,923 | 15,221 | 40,037 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Bioanalizės sistemos - Social security debts
The company had no debts to Sodra
Bioanalizės sistemos - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Bioanalizes sistemos, UAB (code 303339076) is a Private Limited Liability Company engaged in research and experimental development on other natural sciences and engineering. In 2025, the company reported revenue of €303.6K and net profit of €25.7K, corresponding to a profit margin of 8.5%. This was a strong rebound after 2024, when revenue declined to €115.4K and the company posted a net loss of €102.2K, following revenue of €283.0K and net profit of €2.2K in 2023. The latest year therefore shows a clear recovery in both turnover and profitability, with revenue growth of 163.0% year on year and revenue still above the 2023 level. At year-end 2025, total assets stood at €208.4K, equity at €95.9K and liabilities at €114.6K. The equity ratio was 46.0% and debt-to-equity 1.19. Asset turnover reached 1.46x, while return on equity was 26.8% and return on assets 12.3%. Revenue per employee was €43.4K, indicating moderate operating productivity.